Therapy Areas: Vaccines
WuXi Biologics announces structural completion and key equipment arrival at Chengdu microbial manufacturing site
27 April 2026 - WuXi Biologics (HK:2269), a China-based, global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Friday the structural completion and key equipment a...
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
22 April 2026 - Clinical development partner hVIVO plc (AIM: HVO) announced on Wednesday that it has signed a contract with ILiAD Biotechnologies Inc to conduct a pivotal Phase III human challenge tri...
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
20 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Saturday that its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), showed statistically sig...
hVIVO signs influenza human challenge trial agreement with Traws Pharma
14 April 2026 - hVIVO plc (AIM:HVO), a specialist in conducting human challenge trials, announced on Tuesday that it has signed a clinical trial agreement with Traws Pharma (NASDAQ:TRAW), a clinical-s...
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
31 March 2026 - Delonix Bioworks, a clinical-stage biotechnology company developing genetically engineered bacterial vaccines, announced on Monday the initiation of first-in-human (FIH) dosing in a Ph...
GC Biopharma secures first Latin American approval for BARYCELA Inj.
...